Phase II study of single-agent nivolumab in patients with myelofibrosis

New Concepts of Treatment for Patients with Myelofibrosis

(2019) Prithviraj Bose et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Nivolumab combined with ruxolitinib: antagonism or synergy?

(2018) P E Debureaux et al.   ANNALS OF ONCOLOGY

How we treat myelofibrosis after failure of JAK inhibitors

(2018) Animesh Pardanani et al.   BLOOD

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis

(2018) Stine Ulrik Mikkelsen et al.   Cancer Medicine

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

(2018) Naval Daver et al.   Cancer Discovery

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

(2017) Srdan Verstovsek et al.   Journal of Hematology & Oncology

Immunotherapy based approaches in myelofibrosis

(2017) Lucia Masarova et al.   Expert Review of Hematology

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

(2016) S Koschmieder et al.   LEUKEMIA

Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

(2015) Roberto Bellucci et al.   OncoImmunology

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

(2013) A. Tefferi et al.   BLOOD

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

(2013) Richard T Silver et al.   Expert Review of Hematology

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903

(2010) R. A. Mesa et al.   BLOOD

Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY